Global burden of drug-resistant tuberculosis in children: a mathematical modelling study

Peter J Dodd1, Charalambos Sismanidis2, James A Seddon3

  • 1School of Health and Related Research, University of Sheffield, Sheffield, UK.

Insights

Drug-resistant tuberculosis in children is significantly underestimated, with millions infected and thousands developing disease annually. This highlights a critical gap in diagnosis and treatment, impacting global public health strategies for pediatric tuberculosis.

Area of Science:

  • Pediatric infectious diseases
  • Global epidemiology
  • Antimicrobial resistance

Background:

  • Children infected with Mycobacterium tuberculosis face a high risk of developing tuberculosis disease, which is difficult to diagnose.
  • Existing estimates suggest a substantial underreporting of isoniazid-resistant and multidrug-resistant (MDR) tuberculosis cases in children.
  • The burden of drug-resistant tuberculosis infection and disease, including various resistance types and uncertainties, remains unquantified in pediatric populations.

Purpose of the Study:

  • To estimate the global burden of drug-resistant tuberculosis infection and disease in children.
  • To quantify the prevalence of specific drug resistance patterns, including isoniazid monoresistance, MDR, and extensively drug-resistant (XDR) tuberculosis.
  • To provide country-level, regional, and global data on drug-resistant tuberculosis in pediatric populations.

Main Methods:

  • A mathematical model of tuberculosis in children was integrated with drug-resistance pattern analysis.
  • Data from the WHO Global Project on Antituberculosis Drug Resistance Surveillance (1988-2014) were utilized.
  • Bayesian approaches and sampling methods were employed to estimate infection prevalence, disease incidence, and proportions of drug resistance.

Main Results:

  • An estimated 850,000 children developed tuberculosis in 2014, with significant proportions having isoniazid-monoresistant, MDR, and XDR forms.
  • Approximately 67 million children were estimated to be infected with Mycobacterium tuberculosis, including millions with drug-resistant strains.
  • Regions like Africa and Southeast Asia bear the highest numbers, while the Eastern Mediterranean, European, and Western Pacific regions show high proportions of drug resistance.

Conclusions:

  • The actual occurrence of drug-resistant tuberculosis in children far exceeds diagnosed cases, indicating a large reservoir of drug-resistant infection.
  • These findings have significant implications for empirical treatment and preventive therapy strategies in affected regions.
  • There is an urgent need to improve surveillance and diagnostic capabilities for drug-resistant tuberculosis in children worldwide.
Abstract

Related Concept Videos

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
25
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
298
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
660
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
277
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.2K